COO — The Cooper Companies, Inc.

Summary of The Cooper Companies Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Achieved record revenue of $1.08 billion, an 8% increase year-over-year (5% organic growth).
• Non-GAAP EPS: Increased by 26% to $1.21.
• Operating Income: Grew 19%, resulting in a 27.5% operating margin.
• Gross Margin: Held steady at 68.1%.
• Free Cash Flow: Generated $96 million, reducing net debt to $2.3 billion.
• Share Repurchases: $13 million in stock repurchased during the quarter.

2. Strategic Updates and Business Highlights

• CooperVision: Revenue of $724 million, driven by strong performance in the Americas and EMEA, with a 4% organic growth. Continued leadership in the global contact lens market, particularly in daily silicone hydrogel lenses and myopia control products.
• CooperSurgical: Revenue reached $358 million, up 8% (6% organically), with the fertility business growing 10% organically. Strong performance attributed to capital equipment sales and a robust product portfolio.
• Strategic Review: Ongoing evaluation of opportunities to unlock shareholder value, with significant interest in CooperSurgical from multiple parties. Settlements reached in litigation related to a 2023 product recall, allowing the company to focus on strategic options.
• Capital Allocation: Focus on high-return organic growth, maintaining balance sheet flexibility, and increasing share repurchases in the future.

3. Forward Guidance and Outlook

• Revenue Guidance: Full-year revenue expected to be $4.28 billion to $4.32 billion, reflecting 5% to 6% growth (3.5% to 4.5% organic growth).
• CooperVision Guidance: Organic growth expected to be 3.5% to 4.5%, with anticipated declines in Asia Pac due to market softness.
• CooperSurgical Guidance: Unchanged at 4% to 5% organic growth.
• Free Cash Flow: Increased outlook to approximately $650 million for the year, excluding litigation payouts.

4. Bad News, Challenges, or Points of Concern

• Asia Pacific Market Weakness: Anticipated continued declines in the Asia Pac region, particularly in Japan and China, attributed to consumer softness and a shift towards online purchasing and private label products.
• Hydrogel Product Rationalization: Ongoing challenges with legacy hydrogel products impacting performance, expected to continue through 2027.
• Tariff Costs: Anticipated tariffs of approximately $22 million for the fiscal year, with potential refunds not included in guidance.
• Litigation Impact: Settlements related to the recall have been costly, with a $271.6 million charge impacting financials, although largely covered by insurance.

5. Notable Q&A Insights

• Market Dynamics: Management noted a shift in consumer behavior in Asia Pac, with increased online purchases and a preference for glasses impacting contact lens sales.
• Fertility Business Outlook: While the fertility segment showed strong growth, management expects mid-single-digit growth moving forward, influenced by capital sales and market conditions.
• Strategic Review Process: The litigation had previously slowed the strategic review, but with settlements now resolved, the company is moving quickly to explore options for CooperSurgical.
• Operational Efficiency: The company is leveraging back-office efficiencies to maintain profitability while continuing to invest in growth initiatives.

Overall, The Cooper Companies demonstrated strong financial performance in Q2 2026, but faces challenges in specific regions and product lines, particularly in Asia Pac. The strategic review process is ongoing, with a focus on maximizing shareholder value amidst these challenges.